XML 35 R24.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

12 Months Ended

Jun. 30, 2020

Related Party Transactions

Summary of related parties

Property and Equipment


		For the Year Ended
		June 30, 2020			June 30, 2019			June 30, 2018
During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment at cost, to the Company		$	8,638		$	23,666		$	30,321

Accounts Payable- Related Party


		As of
		June 30, 2020			June 30, 2019
Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of certain direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour and; (4) to pay an advance payment equal to twice the amount of the previous months invoice to be applied as a prepayment towards expenses. On October 2, 2018, the Company agreed to enter into an agreement with TheraCour for a waiver of two months worth of prepaid balance in advance of anticipated invoicing until the filing of an IND and the application of the current advance as a credit against current open invoices. Additionally, TheraCour agreed to defer $25,000 per month of development fees, beginning with July 2018 through December 31, 2019. On December 17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour, whereby the Company and TheraCour agreed to the exchange of 100,000 shares of Series A preferred stock with a fair value of $392,669 for $250,000 previously deferred development fees owed to TheraCour, and recognized a loss on the exchange of $142,669. Accounts payable due TheraCour on the reporting date was		$	561,580		$	823,783

Research and Development Costs Paid to Related Party


		For the Year Ended
		June 30,			June 30,			June 30,
		2020			2019			2018
Development fees and other costs charged by TheraCour pursuant to the License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at June 30, 2020, 2019 and 2018		$	2,158,034		$	3,119,863		$	3,176,977

Schedule of mortgage note payable - related party


Mortgage note payable		$	1,100,000
Less: unamortized loan origination fee			(18,013)
Net mortgage note payable		$	1,081,987